Back to resultsA Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
Primary Purpose
Anterior Uveitis
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Dexamethasone
Sponsored by
About this trial
This is an interventional treatment trial for Anterior Uveitis
Eligibility Criteria
Inclusion Criteria: 18 years or older with a diagnosis of non-infectious anterior uveitis in at least one eye Exclusion Criteria: Uncontrolled systemic disease Any active ocular infections
Sites / Locations
Outcomes
Primary Outcome Measures
Anterior Chamber Cell
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00333996
Brief Title
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2011
Overall Recruitment Status
Terminated
Study Start Date
May 2006 (undefined)
Primary Completion Date
March 2007 (Actual)
Study Completion Date
March 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Allergan
4. Oversight
5. Study Description
Brief Summary
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious anterior uveitis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anterior Uveitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
5 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Primary Outcome Measure Information:
Title
Anterior Chamber Cell
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years or older with a diagnosis of non-infectious anterior uveitis in at least one eye
Exclusion Criteria:
Uncontrolled systemic disease
Any active ocular infections
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allergan Inc.
Organizational Affiliation
Allergan
Official's Role
Study Chair
Facility Information:
City
Dallas
State/Province
Texas
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
We'll reach out to this number within 24 hrs